AlleSense raises A$5M Series A to advance NanoMslide cancer diagnostics
What's the deal? AlleSenseDealroom has a profile for this one. Try Dealroom →, a biotech startup spun out of La Trobe University, has raised $5 million to advance its pathology imaging technology that could improve early cancer detection. The Melbourne-based company has developed a nanofabricated microscope slide — the NanoMslide — that uses colour contrast instead of chemical dyes to identify abnormal cells in tissue samples.
The round was led by existing investor Welcome VenturesDealroom has a profile for this one. Try Dealroom →, a special purpose vehicle focused on medical research commercialisation. Breakthrough VictoriaDealroom has a profile for this one. Try Dealroom → contributed $1 million, and the Australian Economic Accelerator (AEA) Innovate grant programme added $2.5 million.
Founded in 2020 by La Trobe researchers Professor Brian Abbey and Dr Eugeniu Balaur, AlleSense previously raised a $2.5 million seed round in 2023. La Trobe University is also an investor. Julian Sutton from Welcome Ventures serves as AlleSense's chief executive officer.
Why now? The NanoMslide — which won the Eureka Prize for the Innovative Use of Technology in 2022 — works with existing optical microscopes, meaning it can slot into current pathology workflows without requiring hospitals to overhaul their equipment. That practical compatibility makes it easier to bring to market.
Prof Abbey said the platform offers faster, more accurate diagnosis for conditions such as breast, skin, and colorectal cancer. "By improving visual contrast in routine tissue samples, the platform has the potential to increase diagnostic concordance, strengthen clinical confidence, and improve the detection of early-stage cancers," he said.
What could go wrong? Medtech startups face long regulatory timelines and the challenge of proving clinical efficacy at scale. AlleSense still needs to demonstrate that its technology performs reliably across diverse real-world settings — and convince pathologists to trust a fundamentally different slide technology in high-stakes diagnoses.
The signal: With half the round coming from government-backed sources — the AEA Innovate grant and Breakthrough Victoria, the latter soon to be merged with LaunchVicDealroom has a profile for this one. Try Dealroom → — AlleSense's raise underscores how public capital remains critical to de-risking deep-tech commercialisation in Australia's life sciences sector. Welcome Ventures' continued backing, combined with CEO Julian Sutton's parallel role as a director of ASX-listed 4DMedical, hints at a playbook for bridging university research and eventual public-market outcomes in medtech.
Read more: startupdaily.net
